MIMEDX to Present at the Canaccord Genuity Musculoskeletal Conference
Marietta, Ga. - March 15, 2022 - MiMedx Group (Nasdaq: MDXG) announced that CEO Timothy R. Wright and CFO Peter M. Carlson will present at the Canaccord Genuity Musculoskeletal Conference in Chicago on March 22 at 10:30 AM CDT. Institutional investors interested in meeting the management can contact their Canaccord Genuity representative. A live webcast will be available on the Company’s website and a replay will be accessible for 30 days post-event. MiMedx specializes in placental biologics, addressing acute and chronic wounds as well as musculoskeletal conditions.
- None.
- None.
MARIETTA, Ga., March 15, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the Canaccord Genuity Musculoskeletal Conference in Chicago on Tuesday, March 22 at 10:30 AM CDT / 11:30 AM EDT. Institutional investors interested in a meeting with management during the conference may reach out to their Canaccord Genuity representative.
Investors and other interested parties may access the live webcast on the Events page of the Investors section of the Company’s website or by clicking here. A replay of the webcast will be available for 30 days on the Company’s website at www.mimedx.com.
About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contact:
Jack Howarth
Investor Relations
404-360-5681
jhowarth@mimedx.com
Contact:
Hilary Dixon
Corporate & Strategic Communications
404-323-4779
hdixon@mimedx.com
FAQ
When will MiMedx Group present at the Canaccord Genuity Musculoskeletal Conference?
Who are the presenters from MiMedx Group at the conference?
How can investors access the MiMedx Group conference presentation?
What is the stock symbol for MiMedx Group?
How long will the webcast replay be available after the MiMedx presentation?
